Alumis Inc. Common Stock

NASDAQ:ALMS

Biotechnology

Healthcare
$4.40 +0.91%

+$0.21 today

Market cap
$568.87M
Beta
-0.54
P/E (TTM)
-12.2
EPS (TTM)
-$1.90
52W Low $2.76High $30.60

Volume 2.01M

Average 1.31M

ALMS Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Alumis Inc. Common StockNASDAQ: ALMS

Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026

Other income / expenses declines year over year

Q2 FY2026 other income / expenses of $4.88M fell 97.5% year over year, behind the -91.0% change in trailing-twelve-month other income / expenses. Sequentially, it fell 8.9% from the prior quarter. Over 3 fiscal years it compounded at +350.3% a year.

Context

  • Other income / expenses amounted to 729.0% of revenue in FY2025.
  • Other income / expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -97.5% toward the trailing-twelve-month pace of -91.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$4.88M-8.9% QoQ
Last fiscal yearDec 2025
$175.32M+2588.5% YoY
LTMJun 2026
$18.29M-91.0% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-97.5%——
1 year+2588.5%——
3-year CAGR+350.3%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
175.32M USD
Year-over-year change
+2588.5%
3-year CAGR
+350.3%

Other Income / Expenses vs competitors

How ALMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -91.0% is the 8th highest of 10, against a peer median of -67.3%.
  • Other income / expenses amounts to 247.2% of revenue for ALMS, versus a peer median of 129.3%.
ALMS Competitors
Other Income / Expenses for ALMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALMSAlumis Inc. Common StockLTM Jun 2026$18.29M USD-91.0%+350.3%247.2%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$10.82M USD-0.5%+57.2%129.3%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$5M USD-50.6%+65.3%—
TLSATiziana Life Sciences LtdFY2025$2.85M USD+399.7%——
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€1.76M EUR-90.8%——
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$1.01M USD-70.6%+29.4%—
IFRXInflaRx N.V.LTM Mar 2026-€440.14K EUR-104.4%-1.4%1500.6%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026-$2.61M USD+55.1%—0.9%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-$5.41M USD-104.4%—9176.3%
ANABAnaptysBio, Inc.LTM Mar 2026-$67.43M USD-67.3%—29.0%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ALMS) —-67.3%+43.3%129.3%

Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00024.05M
Cost of Revenue250K03.15M3.5M
Gross Profit(250K)0(3.15M)20.55M
Gross Margin———85.5%
Research & Development101.05M137.68M265.55M386M
Selling, General & Admin12.55M20.5M35.2M91.86M
Operating Expenses113.6M158.17M297.6M447.76M
Depreciation & Amortization250K1.28M3.15M3.5M
EBITDA(111.68M)(153.71M)(291.08M)(248.39M)
EBITDA Margin———-1032.8%
Operating Income(113.85M)(158.17M)(300.75M)(427.2M)
Operating Margin———-1776.3%
Interest Income1.99M3.37M12.02M14.18M
Interest Expense0000
Other Income / Expenses1.92M3.18M6.52M175.32M
Income Before Tax(111.93M)(154.99M)(294.23M)(251.89M)
Pre-Tax Margin———-1047.3%
Income Tax Expense000(8.56M)
Net Income(111.93M)(154.99M)(294.23M)(243.33M)
Net Margin———-1011.7%
EPS (Basic)(14.93)(2.99)(10.38)(2.32)
EPS (Diluted)(14.93)(2.99)(10.38)(2.32)
Weighted Avg Shares7.5M51.84M28.34M850.3M
Weighted Avg Shares (Diluted)7.5M51.84M28.34M850.3M

Alumis Inc. Common Stock

NASDAQ:ALMS

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.